AntiCancer, Inc.

在癌症治疗的漫漫征程中，每一次突破都承载着无数患者的希望！近年来，γδT细胞犹如一颗闪耀的新星，凭借其独特且强大的免疫特性，强势闯入癌症免疫疗法的研发舞台中心，迅速成为科研人员眼中的 “香饽饽”。如今，多种基于γδT细胞的创新疗法更是如雨后春笋般涌现，纷纷踏入临床试验阶段，为攻克癌症带来了无限可能！ 《Anticancer Research》就曾报道过一则经典案例：一位肾细胞癌患者在根治术后出现肺部转移，随后接受自体体外活化的γδT细胞输注，并配合低剂量IL-2及唑来膦酸治疗。令人惊喜的是，患者实现完全缓解，而且在之后的两年时间里，无需任何额外治疗，病情始终保持稳定！无疑给众多癌症患者注入了一针强心剂，让我们有理由相信，在不久的将来，越来越多的患者将在这些创新疗法的帮助下，走向康复！ ▲截图源自“anticancer research” 一、Vγ2Vδ2 T 细胞助肾癌肺转移患者，实现完全缓解，斩获2年无瘤生存 本例患者是一位61岁的男性，确诊为右侧肾细胞癌，并伴肺转移，此前接受了根治性肾切除术。术后病理显示为透明细胞型肾细胞癌，3级，pT1b分期。随后，患者接受为期三个月的干扰素α（IFN-α）治疗，但CT检查显示肿瘤负荷未见明显变化。 在IFN-α洗脱期一个月后，治疗迎来关键转折：患者通过白细胞分离术获取外周血单核细胞（PBMC），并同步静脉注射IL-2与唑来膦酸（持续30分钟），随后输注活化的Vγ2Vδ2 T细胞。 令人振奋的治疗效果随之出现：CT影像显示的 多发性肺转移灶，在3个疗程后显著缓解，6个疗程后完全消失 。更令人惊喜的是， 患者在完成最后一个疗程治疗后，已持续2年保持完全缓解（CR）状态，且未接受任何针对肾细胞癌的额外治疗 （详见下图）。 ▼下图展示了该患者参与临床试验前、治疗第6个疗程后4个月获得的代表性CT图像 ▲图源“anticancer research”，版权归原作者所有，如无意中侵犯了知识产权，请联系我们删除 这一案例有力证实，基于Vγ2Vδ2T细胞的免疫疗法不仅安全可行，更展现出显著临床价值，为晚期肾细胞癌患者带来全新的治疗希望！ 二、γ-δT细胞：连接天然免疫与获得性免疫的桥梁，兼具抗肿瘤和抗病毒的双重功效 γδ-T细胞是一类罕见的T细胞亚群，又可分为两个主要的亚群，即Vδ1、Vδ2。由于γ、δ链结构的不同，各亚群的功能也有差异，如Vδ2细胞亚群就具有抗肿瘤、抑制病菌感染的特性。 γ-δT细胞虽然仅占T淋巴细胞的0.5%~5%，但其功能全面、强大，被视为T细胞中的“特种部队”。而且无需抗原提呈细胞参与，即可选择性地识别并杀伤肿瘤细胞、被病菌感染的细胞，最近在新型癌症免疫疗法的开发中引起了相当大的关注。 相比其他免疫细胞，γ-δT细胞最独特的优势在于它既有抗肿瘤的功能，同时又具有抗感染的双重作用，是天然免疫与获得性免疫的“桥梁”，在免疫功能的响应中发挥着不可或缺的作用。 ▲图源“cnki”，版权归原作者所有，如无意中侵犯了知识产权，请联系我们删除 三、小编寄语 γδT细胞因具有强大的肿瘤杀伤活性、独特的肿瘤抗原识别能力、卓越的免疫监视特性、易于体外操作等优势，而成为治疗多种癌症的新型候选细胞。值得一提的是，γδT细胞免疫疗法与现有抗癌手段（如手术、化疗和分子靶向药物）的“强强联合”，具有广阔的应用潜力，也是未来抗癌临床研究的关键领域，有望改善癌症患者的预后！想γδT细胞等国内外新兴抗癌疗法更多内容的患者，可以将近期病理检查结果、影像学报告、治疗经历、出院小结等资料，提交至 全球肿瘤医生网医学部 ，进行初步评估或了解详细的入排标准。 四、参考资料 [1]Kobayashi H,et al. Complete remission of lung metastasis following adoptive immunotherapy using activated autologous γδ T-cells in a patient with renal cell carcinoma[J]. Anticancer research, 2010, 30(2): 575-579. https://ar.iiarjournals.org/content/30/2/575.long 本文为全球肿瘤医生网原创，未经授权严禁转载

SAN DIEGO--(BUSINESS WIRE)-- AntiCancer Inc. announced it has just received US Patent 11,871,731 that describes a method to increase the rate of establishment of patient tumors in mice to close to 100%. Previously the establishment rates were much lower, in many cases only 10-20% in laboratories around the world. “The new method allows, for the first time, large scale and commercial success of establishing mouse models for each cancer patient to individualize and optimize their cancer therapy, as well as banking their tumors after establishment for future therapy,” said Chihiro Hozumi, co-inventor of the patent and General Manager of AntiCancer’s Japanese subsidiary, AntiCancer Japan. “The new method is especially important as almost all cancer patients can now have their own individualized clinically-concordant PDOX mouse model,” said AntiCancer Senior Mouse-Model Scientist Jose Reynoso. “The new method facilitates the discovery of effective cancer drugs, since many more mouse models of cancer with patient tumors will be available for testing of novel cancer drugs,” said AntiCancer Senior Scientist Qinghong Han. AntiCancer Inc. of San Diego was established in 1984 and is celebrating its 40th anniversary. AntiCancer is a world leader in developing individualized cancer therapy, including contract research, using its proprietary PDOX mouse model which it has developed since 1987, and most closely represents the cancer patient. View source version on businesswire.com: Contacts Qinghong Han, MD all@anticancer.com Source: AntiCancer Inc. View this news release online at:

SAN DIEGO--(BUSINESS WIRE)-- AntiCancer Inc. of San Diego has announced its PDOX mouse model of human cancer patients has demonstrated high concordance of chemotherapy in the mouse and patient. “This new result means AntiCancer has made the first steps for precise, individualized cancer chemotherapy,” said Qinghong Han, Senior Scientist at AntiCancer Inc. “The PDOX mouse model has the patient’s tumor implanted in the same organ in the mouse as it was in the patient enabling very accurate prediction of chemotherapy outcome for the patient,” said Dr. Han. “AntiCancer’s technique of patient-tumor establishment in mice is close to 100%, making the PDOX model available potentially to all patients,” technique-inventor and AntiCancer-Japan General Manager Chihiro Hozumi said. AntiCancer has published 165 scientific papers on its PDOX model since 1991. The latest paper on clinical concordance of the PDOX model is published in the October 2023 issue of Anticancer Research. AntiCancer Inc., San Diego, is a world leader in mouse models of cancer; small-animal imaging; methionine-restriction treatment of cancer; bacterial therapy of cancer, adult stem cells for regenerative medicine, in vitro assays of cancer therapy, a pioneer in fluorescence-guided surgery, and more, demonstrated in 1200 scientific publications and almost 200 patents. AntiCancer Inc. was founded in 1984. View source version on businesswire.com: Contacts Qinghong Han, MD all@anticancer.com Source: AntiCancer Inc. View this news release online at: